MCP AbD Serotec
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/mcp.R300004-MCP200 on June 23, 2003.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
R300004-MCP200v1
2/6/388    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Admon, A.
Right arrow Articles by Ziv, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Admon, A.
Right arrow Articles by Ziv, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular & Cellular Proteomics 2:388-398, 2003.
© 2003 by The American Society for Biochemistry and Molecular Biology, Inc.

Review

Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides*

Arie Admon{ddagger}, Eilon Barnea and Tamar Ziv

From the Department of Biology, Technion, Haifa 32000, Israel

The major histocompatibility complex (MHC) peptide repertoire of cancer cells serves both as a source for new tumor antigens for development of cancer immunotherapy and as a rich information resource about the protein content of the cancer cells (their proteome). Thousands of different MHC peptides are normally displayed by each cell, where most of them are derived from different proteins and thus represent most of the cellular proteome. However, in contrast to standard proteomics, which surveys the cellular protein contents, analyses of the MHC peptide repertoire correspond more to the rapidly degrading proteins in the cells (i.e. the transient proteome). MHC peptides can be efficiently purified by affinity chromatography from membranal MHC molecules, or preferably following transfection of vectors for expression of recombinant soluble MHC molecules. The purified peptides are resolved and analyzed by capillary high-pressure liquid chromatography-electrospray ionization-tandem mass spectrometry, and the data are deciphered with new software tools enabling the creation of large databanks of MHC peptides displayed by different cell types and by different MHC haplotypes. These lists of identified MHC peptides can now be used for searching new tumor antigens, and for identification of proteins whose rapid degradation is significant to cancer progression and metastasis. These lists can also be used for identification of new proteins of yet unknown function that are not detected by standard proteomics approaches. This review focuses on the presentation, identification and analysis of MHC peptides significant for cancer immunotherapy. It is also concerned with the aspects of human proteomics observed through large-scale analyses of MHC peptides.

{ddagger} To whom correspondence should be addressed: Department of Biology, Technion—Israel Institute of Technology, Haifa 32000, Israel. Tel.: 972-4-8293407; Fax: 972-4-8225153; E-mail: admon{at}tx.technion.ac.il


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JEMHome page
M.-H. Fortier, E. Caron, M.-P. Hardy, G. Voisin, S. Lemieux, C. Perreault, and P. Thibault
The MHC class I peptide repertoire is molded by the transcriptome
J. Exp. Med., March 17, 2008; 205(3): 595 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
A. O. Weinzierl, C. Lemmel, O. Schoor, M. Muller, T. Kruger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingel, H.-G. Rammensee, et al.
Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface
Mol. Cell. Proteomics, January 1, 2007; 6(1): 102 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. L. Zarling, J. M. Polefrone, A. M. Evans, L. M. Mikesh, J. Shabanowitz, S. T. Lewis, V. H. Engelhard, and D. F. Hunt
From the Cover: Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy
PNAS, October 3, 2006; 103(40): 14889 - 14894.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
E. Milner, E. Barnea, I. Beer, and A. Admon
The Turnover Kinetics of Major Histocompatibility Complex Peptides of Human Cancer Cells
Mol. Cell. Proteomics, February 1, 2006; 5(2): 357 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
A. W. Purcell and J. J. Gorman
Immunoproteomics: Mass Spectrometry-based Methods to Study the Targets of the Immune Response
Mol. Cell. Proteomics, March 1, 2004; 3(3): 193 - 208.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.